| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| Other Sizes |
Purity: ≥98%
SB273005 (SB 273005; SB-273005) is a novel and potent integrin inhibitor with potential usefulness in bone resorption, osteoporosis and arthritis. It inhibits integrin αvβ3 receptor and αvβ5 receptor with Ki values of 1.2 nM and 0.3 nM, respectively. SB 273005 binds αvβ3 and αvβ5 with low nM affinity, but binds weakly to integrins αIIbβ3 and α5β1. SB 273005 inhibits αvβ3-mediated cell adhesion with an IC50 value of 3 nM, endothelial cell migration with an IC50 of 1.8 nM, and osteoclast-mediated bone resorption with an IC50 of 11 nM in vitro.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
J Med Chem.2000 Jan 13;43(1):22-6;Arthritis Rheum.2001 Jan;44(1):128-37.
|
| Molecular Formula |
C22H24F3N3O4
|
|
|---|---|---|
| Molecular Weight |
451.44
|
|
| Exact Mass |
451.171
|
|
| Elemental Analysis |
C, 58.53; H, 5.36; F, 12.63; N, 9.31; O, 14.18
|
|
| CAS # |
205678-31-5
|
|
| Related CAS # |
|
|
| PubChem CID |
9868426
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
662.9±55.0 °C at 760 mmHg
|
|
| Flash Point |
354.7±31.5 °C
|
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
|
| Index of Refraction |
1.563
|
|
| LogP |
3.16
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
9
|
|
| Rotatable Bond Count |
8
|
|
| Heavy Atom Count |
32
|
|
| Complexity |
648
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
FC(C([H])([H])N1C([C@]([H])(C([H])([H])C(=O)O[H])C([H])([H])C2C([H])=C([H])C(=C([H])C=2C1([H])[H])OC([H])([H])C([H])([H])C1C([H])=C([H])C([H])=C(N([H])C([H])([H])[H])N=1)=O)(F)F
|
|
| InChi Key |
KSSPHFGIOASRDE-HNNXBMFYSA-N
|
|
| InChi Code |
InChI=1S/C22H24F3N3O4/c1-26-19-4-2-3-17(27-19)7-8-32-18-6-5-14-9-15(11-20(29)30)21(31)28(12-16(14)10-18)13-22(23,24)25/h2-6,10,15H,7-9,11-13H2,1H3,(H,26,27)(H,29,30)/t15-/m0/s1
|
|
| Chemical Name |
2-[(4S)-8-[2-[6-(Methylamino)pyridin-2-yl]ethoxy]-3-oxo-2-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-2-benzazepin-4-yl]acetic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 90 mg/mL (199.4 mM)
Water: 1 mg/mL (Insoluble) Ethanol: 16 mg/mL (35.4 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2151 mL | 11.0757 mL | 22.1513 mL | |
| 5 mM | 0.4430 mL | 2.2151 mL | 4.4303 mL | |
| 10 mM | 0.2215 mL | 1.1076 mL | 2.2151 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA